Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;207(3):1122-1126.
doi: 10.1111/bjh.20247. Epub 2025 Jul 2.

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM

Maud D'Aveni  1 , Laurence Schenone  1 , Jose Miguel Torregrosa  2 , Jean Pardo  3 , Aspasia Stamatoullas  4 , Colombe Saillard  5 , Sylvain Thépot  6 , Sophie Dimicoli  7 , Clemence Santana  8 , Etienne Daguindau  9 , Francianne Paul  10 , Lenaig Le Clech  11 , Sophie Park  12 , Thomas Cluzeau  13 , Etienne Paubelle  14 , Anne-Laure Taksin-Bressot  15 , Fatiha Chermat  16 , Lionel Adès  3 , Pierre Fenaux  3 , Thibault Comont  17
Affiliations

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM

Maud D'Aveni et al. Br J Haematol. 2025 Sep.
No abstract available

Keywords: luspatercept; myelodysplastic neoplasm; real‐life.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interests: Maud D'Aveni has participated in consulting or advisory boards for Abbvie, BMS and Sanofi and travel grants from Sanofi. Thibault Comont has participated in consulting or advisory boards for Abbvie, AMGEN, BMS, Grifols, Novartis, and has received travel grants from Abbvie, AMGEN, BMS, Grifols, Novartis, has received research funding from Novartis and has received payment for speaker bureau from Abbvie, AMGEN, BMS, Grifols, Novartis. Jose Miguel Torregrosa has participated in consulting advisory boards for BMS, Alexion, Novartis, Sobi, Sellas Biosciences, received travel grants from Sellas Biosciences, Novartis and Alexion. Aspasia Stamatoullas has received travel grants from BMS, Takeda, AbbVie. Lenaig Le Clech has participated in advisory boards for Abbvie. Etienne Daguindau has received consulting fees from Abbvie, BMS, Amgen, Sanofi, Novartis, Gilead‐Kite, Takeda, Johnson & Johnson and Incyte, research funding from BMS, Novartis and travel accommodation from Abbvie. Clemence Santana has participated in advisory boards for Abbvie and BMS.

Figures

FIGURE 1
FIGURE 1
Treatment trajectory in the 54 patients treated with luspatercept + ESA at inclusion in the real‐world study. (A) Sankey flow diagram describing RBC dependency status during weeks 1–16 of luspatercept and ESA association. (B) Response evaluation after 16 weeks of luspatercept + ESA association, according to the IWG 2018 in the 38 evaluable patients. ESA, erythropoietin‐stimulating agent; RBC, red blood cell.
See this image and copyright information in PMC

References

    1. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, et al. A phase 3 randomized, placebo‐controlled study assessing the efficacy and safety of epoetin‐alpha in anemic patients with low‐risk MDS. Leukemia. 2018;32:2648–2658. - PMC - PubMed
    1. Fenaux P, Platzbecker U, Mufti GJ, Garcia‐Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower‐risk myelodysplastic syndromes. N Engl J Med. 2020;382:140–151. - PubMed
    1. Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T)—“2021 update on diagnosis, risk‐stratification, and management”. Am J Hematol. 2021;96:379–394. - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. - PubMed
    1. Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, et al. Lenalidomide with or without erythropoietin in transfusion‐dependent erythropoiesis‐stimulating agent‐refractory lower‐risk MDS without 5q deletion. Leukemia. 2016;30:897–905. - PubMed

LinkOut - more resources